Cite
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma.
MLA
Afrough, Aimaz, et al. “Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma.” Cancers, vol. 15, no. 19, Oct. 2023, p. 4894. EBSCOhost, https://doi.org/10.3390/cancers15194894.
APA
Afrough, A., Atrash, S., Paul, B., Ouchveridze, E., Ahmed, N., Mahmoudjafari, Z., Bashir, A., Alkharabsheh, O., Hashmi, H., & Abdallah, A.-O. (2023). Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma. Cancers, 15(19), 4894. https://doi.org/10.3390/cancers15194894
Chicago
Afrough, Aimaz, Shebli Atrash, Barry Paul, Evguenia Ouchveridze, Nausheen Ahmed, Zahra Mahmoudjafari, Anam Bashir, Omar Alkharabsheh, Hamza Hashmi, and Al-Ola Abdallah. 2023. “Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab–Naïve Relapsed Multiple Myeloma.” Cancers 15 (19): 4894. doi:10.3390/cancers15194894.